BMO Capital analyst Alex Arfaei maintained a Buy rating on Pfizer (NYSE: PFE) today and set a price target of $47. The company’s shares closed on Friday at $44.50, close to its 52-week high of $45.81.
According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.8% and a 73.0% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Eli Lilly & Co.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $44.45 average price target, representing a -0.1% downside. In a report issued on October 7, Cantor Fitzgerald also maintained a Buy rating on the stock with a $45 price target.
.
See today’s analyst top recommended stocks >>
Pfizer’s market cap is currently $260.9B and has a P/E ratio of 11.93. The company has a Price to Book ratio of 3.74.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
